214 related articles for article (PubMed ID: 37400148)
1. Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis.
Panagopoulos I; Andersen K; Brunetti M; Gorunova L; Davidson B; Lund-Iversen M; Micci F; Heim S
Cancer Genomics Proteomics; 2023; 20(4):363-374. PubMed ID: 37400148
[TBL] [Abstract][Full Text] [Related]
2. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
5. A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Desmeules P; Joubert P; Zhang L; Al-Ahmadie HA; Fletcher CD; Vakiani E; Delair DF; Rekhtman N; Ladanyi M; Travis WD; Antonescu CR
Am J Surg Pathol; 2017 Jul; 41(7):980-988. PubMed ID: 28505004
[TBL] [Abstract][Full Text] [Related]
6. EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity.
Dermawan JK; Torrence D; Lee CH; Villafania L; Mullaney KA; DiNapoli S; Sukhadia P; Benayed R; Borsu L; Agaram NP; Nash GM; Dickson BC; Benhamida J; Antonescu CR
Genes Chromosomes Cancer; 2022 Oct; 61(10):592-602. PubMed ID: 35665561
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
8. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
9. Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13).
Panagopoulos I; Gorunova L; Davidson B; Heim S
Cancer Lett; 2015 Feb; 357(2):502-9. PubMed ID: 25484136
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
13. RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12).
Panagopoulos I; Thorsen J; Gorunova L; Micci F; Haugom L; Davidson B; Heim S
Genes Chromosomes Cancer; 2013 Aug; 52(8):733-40. PubMed ID: 23630070
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
Krasinskas AM; Bartlett DL; Cieply K; Dacic S
Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
[TBL] [Abstract][Full Text] [Related]
15. Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma.
Teixeira MR; Giercksky KE; Ikonomou IM; Heim S
Cancer Genet Cytogenet; 1998 May; 103(1):73-5. PubMed ID: 9595051
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
17. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma.
Hu Q; Akatsuka S; Yamashita Y; Ohara H; Nagai H; Okazaki Y; Takahashi T; Toyokuni S
Lab Invest; 2010 Mar; 90(3):360-73. PubMed ID: 20065947
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma.
Kleymenova EV; Bianchi AA; Kley N; Pylev LN; Walker CL
Mol Carcinog; 1997 Jan; 18(1):54-60. PubMed ID: 9022813
[TBL] [Abstract][Full Text] [Related]
19. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
